ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 876

Damage Develops Early and Is Common in Children with Chronic Systemic Vasculitis

Lorraine O'Neill1, Marinka Twilt2, Susanne Benseler3, Dirk Föll4, David A. Cabral5 and Raashid Luqmani6, 1University of Oxford, Oxford, United Kingdom, 2Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 3Pediatrics, University of Calgary, Toronto, ON, Canada, 4University of Muenster, Muenster, Germany, 5Pediatrics/Rm K4-121, BC Children's Hospital, Vancouver, BC, Canada, 6Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: pediatric rheumatology and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

 The chronic
primary systemic vasculitides are a group of rare
conditions with affected patients subject to a significant burden of morbidity
from both the disease itself and its treatment. In adult vasculitides,
the Vasculitis Damage Index (VDI) is a validated
damage assessment tool and an integral outcome measure. The lack of such a
validated index in childhood vasculitis has contributed to the paucity of
outcome data in children with vasculitis. The aim of this study was to use a
modification of the adult VDI to assess damage accrual
in a cohort of children with primary systemic vasculitis recruited to A
Registry of Childhood Vasculitis (ARCHiVe), a
web-based registry founded in 2007 by the Canadian/US based Childhood Arthritis
and Rheumatology Research Alliance (CARRA).

Methods:

 A multi-centre
cohort study of children enrolled into ARCHiVe was
conducted. Children were included if they were followed for at least 12 months
and had a PVDI completed.

Results:

 A total of 74
children were included in the study. 
65% were female. The mean age was 11.8 years (range 2-18). Granulomatosis with polyangiitis
(GPA) was the most frequently encountered diagnosis (Table 1).  At baseline, the median Paediatric Vasculitis Activity Score (PVAS)
was 12 (range 2-31). At 12 months, 39/74 children (52.7%) had accumulated at
least one item of damage (PVDI=1 in 18 patients, PVDI=2 in 14, PVDI=3 in 4, PVDI=4 in 1 and PVDI=5 in
2).  The most commonly recorded
damage items were in the “Other” section (consisting of significant striae [16.2%], chronic cough [5.4%] and vocal cord
paralysis [5.4%]), followed by “Renal” due to end stage renal failure (9.5%)
and proteinuria (9.5%) and “Pulmonary” due to
impaired lung function (9.5%) as shown in Figure 1.

 Conclusion:

 Within the first year of disease more than 50% of children
with systemic vasculitis have accumulated damage. The information gained from
this study provides a useful data driven basis for future development and
validation of a damage assessment tool in paediatric
vasculitis.

Table 1

Diagnosis

No of Patients

Percentage %

Granulomatosis with Polyangiitis (GPA)

43

58.1

Limited Granulomatosis with Polyangiitis

8

10.8

Takayasu Arteritis

7

9.5

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

5

6.8

Microscopic Polyangiitis (MPA)

3

4

Isolated Renal Microscopic Polyangiitis

3

4

Polyarteritis Nodosa

3

4

Unclassified Primary Vasculitis

1

1.4

ANCA positive pauci-immune glomerulonephritis

1

1.4

Figure 1

Number of patients with systemic vasculitis showing items of damage using the provisional pediatric modification of the VDI

Text Box: Number of patients with systemic vasculitis showing items of damage using the provisional pediatric modification of the VDI


Disclosure: L. O'Neill, None; M. Twilt, None; S. Benseler, None; D. Föll, None; D. A. Cabral, None; R. Luqmani, GSK, 5,Chemocentryx, 5,Roche Pharmaceuticals, 5.

To cite this abstract in AMA style:

O'Neill L, Twilt M, Benseler S, Föll D, Cabral DA, Luqmani R. Damage Develops Early and Is Common in Children with Chronic Systemic Vasculitis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/damage-develops-early-and-is-common-in-children-with-chronic-systemic-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/damage-develops-early-and-is-common-in-children-with-chronic-systemic-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology